Abingdon Health inks sales and distribution agreement with BioSure UK

Rapid tests developer Abingdon Health has signed a non-exclusive sales and distribution agreement in the UK and Europe for its AbC-19 rapid neutralising antibody test with BioSure UK.

Abingdon said on Wednesday that it will establish a strategic distribution relationship with BioSure to enable both firms to identify and maximise opportunities for the sale of the AbC-19 rapid neutralising antibody test in the UK and European territories.

The AIM-listed group stated healthcare, workplace and pharmacy settings will be prioritised, with antibody testing becoming "even more relevant" as vaccination programmes scale.

Chief executive Chris Yates said: "The nature of SARS-CoV-2 testing is changing. Where antibody tests were once predominantly used for charting the spread of infection within communities, today they emerging as a key pillar of large-scale immunisation campaigns.

"Rapid Antibody tests such as AbC-19 that target the full trimeric spike can help policymakers and healthcare networks further understand immunity to Covid-19 and the effectiveness of vaccine programmes."

As of 1050 GMT, Abingdon shares had shot up 7.40% to 103.64p.